Medtronic ( NYSE:MDT ) Full Year 2024 Results Key Financial Results Revenue: US$32.4b (up 3.6% from FY 2023). Net...
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.